Yeda Research and Develpment & Co. Ltd

University of Colorado

Merck Serono S. A.

Daniela Novick

Menachem Rubinstein

Charles A Dinarello

Soo Hyun Kim

Dina G Fischer

Michel Revel

Nathan Tal

David Wallach

Hartmut Engelmann

Yolande Chvatchko

Christine Plater-Zyberk

Batya Cohen

Louise Chen

Yves Mory

Dan Aderka

Soo-Hyun Kim

Boris Schwartsburd

Leonid Reznikov

Vladimir Hurgin

Bianling Liu

Pierre Graber

Patricia Orchansky

Eran Hadas

Giamila Fantuzzi

Santer Van Deventer

The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use.

Method for screening inhibitors of interleukin-32 (IL-32)

Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.

Antibodies against interleukin-18 binding protein, their preparation and use

An isolated DNA molecule has the sequence of encoding a fragment of encoding Tumor Necrosis Factor (TNF) Binding Protein II. It has a length sufficient to serve as an immunogen for raising antibodies against a polypeptide that is a fragment of TNF Binding Protein II. The DNA may be used to produce replicable expression vehicles and prokaryotic or eukaryotic expression host cells. Such host cells may be used to produce polypeptides encoded by such DNA molecules.

Isolated cDNA encoding tumor necrosis factor binding protein II, its purification, and vectors, hosts and processes using such cDNA

The present invention relates to the promoter of interleukin-18 binding protein (IL-18BP), to its preparation and use.

Promoter to IL-18BP, its preparation and use

Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vecotors useful for their expression in humans and other mammals, antibodies against them are also provided.

Interleukin-18 binding proteins, their preparation and use

The present invention provides a method of treatment or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock, and sepsis related to cardiac dysfunction.

Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis

Interleukin-18 binding proteins which are capable of binding IL-18 and of modulating and/or blocking IL-18 activity are provided. Methods for the isolation and recombinant production, DNAs encoding them. DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided. Therapeutic uses of IL-18 binding proteins and further inhibitors of IL-18 are also provided according to the invention.

Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins

Biologically active molecules are produced from their biologically inactive precursors by mutation of their native cleavage site to a site which is capable of being cleaved by a protease, and cleavage of the mutated molecule to yield a biologically active molecule.

Preparation of biologically active molecules

DNA encoding a soluble LDL receptor protein, is provided, as are vectors, cell lines and processes for the production of the protein, mutein or fragment. The soluble LDL receptor protein, and its muteins and fragments, are useful in protection of mammals against viral infections.

Soluble LDL receptor, its production and use

Interleukin-18 binding proteins, their preparation and use for blocking the activity of IL-18

Interferon &agr;/&bgr; binding proteins are provided, which are capable of modulating the activity of interferon-&agr; subtypes as well as interferon-&bgr;. Cloning of DNA molecules encoding these proteins, expression in host cells and antibodies against the proteins are also provided.

Interferon-&agr;/&bgr; binding protein, its preparation and use

A soluble LDL receptor protein is provided. It can be isolated from cells that have been treated with an interferon, isolated from the urine of healthy human individuals or produced by recombinant techniques. The soluble LDL receptor protein is useful in protection of mammals against viral infections.

Growing community of inventors

Rehovot, Israel

Daniela Novick